Quick Answer
Axsome Therapeutics, Inc. reported Total Revenue of $638.50 million for the year ending 2025.
- Axsome Therapeutics, Inc. showed an increase of +65.5% in Total Revenue from 2024 to 2025.
- This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $8.82 million | Q3 2022: $16.85 million | Q1 2023: $94.58 million | Q2 2023: $46.70 million | Q3 2023: $57.79 million | Q1 2024: $75.00 million | Q2 2024: $87.17 million | Q3 2024: $104.76 million | Q1 2025: $121.46 million | Q2 2025: $150.04 million | Q3 2025: $170.99 million.
- Over the full 4 years of available data (2022 to 2025), Axsome Therapeutics, Inc.'s Total Revenue has grown by 1,176.0%.
- Historical annual values: Fiscal year 2025: $638.50 million | Fiscal year 2024: $385.69 million | Fiscal year 2023: $270.60 million | Fiscal year 2022: $50.04 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: